#Repatha copay card trial#

Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha ®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

#Repatha copay card trial#

If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha ®, treat according to the standard of care, and monitor until signs and symptoms resolve.Īdverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha ® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.įrom a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha ®-treated and placebo-treated patients, respectively.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha ®.

Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha ®.

Contraindication: Repatha ® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha ®.